RepriceRocketRider

Here for atypical stock returns from reprice opportunities

[Stock PlayMaker 🌐 @stockplaymaker1]

TRUMP : WE’LL HANDLE CUBA AFTER WE TAKE CARE OF IRAN

Cubans right now… just minding their own business

[RepriceRocketRider @RepriceRockets1]

@alifarhat79 Definitely not $CSDX then...

[RepriceRocketRider @RepriceRockets1]

@stockplaymaker1 $CSDX but nano is subjective

[RepriceRocketRider @RepriceRockets1]

@stockplaymaker1 Dude, $CSDX needs some luvin. Even the market makers are bored with it. Even a small retail churn could send it to 40 cents with ease. It's done it many times sub dime.

[RepriceRocketRider @RepriceRockets1]

@alifarhat79 @Not_KevinWarsh Hopefully Not_KevinWarsh informs the world about $CSDX @CSDX_CSDCorp like this amazing investor did 👇

[Stock Picks NYC @StockPicksNYC]

$CSDX one to look into asap tick tock. Their CS Protect-Hydrogel is currently under FDA review

High value/low competition niche(hydrogel spacers)

•SpaceOAR™ Hydrogel System acquired by $BSX Boston Scientific for $500M

•Barrigel® acquired by Telefex $TFX for $600M

And literally no other direct competitors in market

This is a pretty big OTC play. High value/low competition niche(hydrogel spacers), which seen major buyouts in the past. In the range of $500M-$600M.

Not your typical OTC play. The potential is just massive on this one

[Not Jerome Powell @alifarhat79]

You know what to do @Not_KevinWarsh lmao

[RepriceRocketRider @RepriceRockets1]

@stockplaymaker1 That's what few of us $CSDX retail shareholders left feel. Sure hope it ends with the luck part working out.

[Not Jerome Powell @alifarhat79]

Bitcoin Investors

[RepriceRocketRider @RepriceRockets1]

@alifarhat79 Sad to say for $BTC / $MSTR.. true for $CSDX investors too. But, the tide may change. Tsunami of momentum may arrive! If this 👇 happens:

[Stock Picks NYC @StockPicksNYC]

$CSDX one to look into asap tick tock. Their CS Protect-Hydrogel is currently under FDA review

High value/low competition niche(hydrogel spacers)

•SpaceOAR™ Hydrogel System acquired by $BSX Boston Scientific for $500M

•Barrigel® acquired by Telefex $TFX for $600M

And literally no other direct competitors in market

This is a pretty big OTC play. High value/low competition niche(hydrogel spacers), which seen major buyouts in the past. In the range of $500M-$600M.

Not your typical OTC play. The potential is just massive on this one

[RepriceRocketRider @RepriceRockets1]

$BSX would you please offer $CSDX a buyout? Please & thank you 😊

[RepriceRocketRider @RepriceRockets1]

$IBIT is getting slaughtered since October. Same for $CSDX too. But if the news breaks from this post below, giddy up cowboys n cowgirls. 🤠
@CSDX_CSDCorp just needs to get their 💩 together ❤️

[RepriceRocketRider @RepriceRockets1]

$MSTR $SPIR $AMD

[RepriceRocketRider @RepriceRockets1]

$IBIT is getting slaughtered since October. Same for $CSDX too. But if the news breaks from this post below, giddy up cowboys n cowgirls. 🤠
@CSDX_CSDCorp just needs to get their 💩 together ❤️

[RepriceRocketRider @RepriceRockets1]

$IBIT is getting slaughtered since October. Same for $CSDX too. But if the news breaks from this post below, giddy up cowboys n cowgirls. 🤠
@CSDX_CSDCorp just needs to get their 💩 together ❤️

[Stock Picks NYC @StockPicksNYC]

$CSDX one to look into asap tick tock. Their CS Protect-Hydrogel is currently under FDA review

High value/low competition niche(hydrogel spacers)

•SpaceOAR™ Hydrogel System acquired by $BSX Boston Scientific for $500M

•Barrigel® acquired by Telefex $TFX for $600M

And literally no other direct competitors in market

This is a pretty big OTC play. High value/low competition niche(hydrogel spacers), which seen major buyouts in the past. In the range of $500M-$600M.

Not your typical OTC play. The potential is just massive on this one

[RepriceRocketRider @RepriceRockets1]

$MSTR & $CSDX charts are looking too similar. Brutal 2026, no lie. The only bright side is that @CSDX_CSDCorp may announce FDA approval for their hydrogel any day now. Or not. But if they do? $BTC won't hold a green candle next to where this ticket could 🚀🚀🚀
Molten Magma 🌋

[RepriceRocketRider @RepriceRockets1]

Bitcoin & $CSDX charts are looking too similar. Brutal 2026, no lie. The only bright side is that CS Diagnostics may announce FDA approval for their hydrogel any day now. Or not. But if they do? $BTC won't hold a green candle next to where this ticket could 🚀🚀🚀

[Stock Picks NYC @StockPicksNYC]

$CSDX one to look into asap tick tock. Their CS Protect-Hydrogel is currently under FDA review

High value/low competition niche(hydrogel spacers)

•SpaceOAR™ Hydrogel System acquired by $BSX Boston Scientific for $500M

•Barrigel® acquired by Telefex $TFX for $600M

And literally no other direct competitors in market

This is a pretty big OTC play. High value/low competition niche(hydrogel spacers), which seen major buyouts in the past. In the range of $500M-$600M.

Not your typical OTC play. The potential is just massive on this one

[RepriceRocketRider @RepriceRockets1]

Bitcoin & $CSDX charts are looking too similar. Brutal 2026, no lie. The only bright side is that @CSDX_CSDCorp may announce FDA approval for their hydrogel any day now. Or not. But if they do? $BTC won't hold a green candle next to where this ticket could 🚀🚀🚀
to the bold!

[RepriceRocketRider @RepriceRockets1]

👋 hello there, welcome to the $CSDX anonymous support group. Please state your name & how long you've been holding. This is a safe space so if you're a bag holder like many here, be comforted. Maybe mgmt will stop treating us like mushrooms "soon"?
@CSDX_CSDCorp @csinterpharm

[RepriceRocketRider @RepriceRockets1]

$CSDX shareholders who watched the mgmt Investor Conference webinar in 2025 June waiting to see the results. Thomas said ~12 months for FDA hydrogel from then. Accurate still? Or nah. The March '25 PR said approvals in 3-4 months. It's been 15 months since that. @CSDX_CSDCorp 🦗

[RepriceRocketRider @RepriceRockets1]

@CSDX_CSDCorp

"A good plan violently executed NOW is better than a perfect plan executed next week." - General Georgs S. Patton

$CSDX facing serious raison d'etre in 2026.

[RepriceRocketRider @RepriceRockets1]

$CSDX shareholders waiting for @CSDX_CSDCorp to graduate to big leagues investor relations. We'd take "fake it til you make it" efforts at this point. Le mieux est l'ennemi du bien!

[RepriceRocketRider @RepriceRockets1]

@FinanceLancelot You did call this months ago. I remember